{'fraction_non_alphanumeric': 0.016224188790560472, 'fraction_numerical': 0.011799410029498525, 'mean_word_length': 5.40566037735849, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Pharmacophysiologic and clinical aspects of oral contraceptives.


 To date, 2 synthetic estrogens and 8 progestogens have been incorporated in the marketed oral contraceptives (OCs) in the US. At present 21 pills are available representing 14 different estrogen and progestin combinations and 1 minidose progestogen (alone). 2 OCs utilizing substituted progesterone as the progestin component have been withdrawn from the market. All of the OCs now available in the US utilize substituted testosterone as progestins. The trend is toward prescribing low estrogen dose OCs perhaps resulting from the statistical relationship between higher estrogen dose OCs and thromboembolism.
